文献速递心外重症与机械循环支持

REVIVAL研究:门诊晚期心衰患者生活质量与VAD治疗偏好

Quality of life and treatment preference for ventricular assist device therapy in ambulatory advanced heart failure: A report from the REVIVAL study.
PubMed 文献 · J Heart Lung Transplant · 2019-11-20

REVIVAL研究为前瞻性多中心队列,纳入400例门诊晚期慢性收缩性心衰患者,评估入组时健康相关生活质量(KCCQ、EQ-5D VAS、PSARL)与VAD治疗偏好的关联。结果显示KCCQ与VAS与NYHA分级和INTERMACS profile显著相关,但与VAD偏好关联弱且绝对差异小,VAD偏好与年龄、VAS、PSARL等关键临床特征无关。

要点

  • 门诊晚期心衰患者基线KCCQ中位64、VAS中位65、PSARL中位7年。
  • KCCQ与VAS和NYHA分级及INTERMACS profile显著相关(p<0.005)。
  • VAD治疗偏好与KCCQ相关但绝对差异小,与年龄、VAS、PSARL无关。

核心结论

  • 健康相关生活质量与患者VAD治疗偏好之间缺乏强关联。
  • 需要更好理解患者对疾病的感知及其与生活质量结局、临床医生风险评估和患者决策的关系。

研究设计与样本

  • REVIVAL研究为前瞻性多中心队列,纳入400例门诊晚期慢性收缩性心衰患者。
  • 基线评估包括KCCQ、EQ-5D-3L VAS和PSARL,采用描述性统计和Spearman相关分析。

主要发现

  • 中位年龄60岁,75%为男性,中位左心室射血分数20%。
  • 基线KCCQ汇总评分中位64(25th, 75th:48, 78),VAS中位65(50, 75),PSARL中位7年(5, 10)。
  • 基线KCCQ和VAS与NYHA分级及INTERMACS profile显著相关(所有比较p<0.005)。
  • 基线KCCQ和VAS与PSARL呈 modest 相关(相关系数分别为0.45和0.35;p<0.001),许多患者对预期生存过于乐观。
  • VAD治疗偏好与KCCQ评分相关(p<0.031),但绝对差异小;与年龄、VAS、PSARL等关键临床特征无关。

关键数值与推荐

  • KCCQ与NYHA分级和INTERMACS profile比较p<0.005。
  • KCCQ与PSARL相关系数0.45(p<0.001),VAS与PSARL相关系数0.35(p<0.001)。
  • VAD治疗偏好与KCCQ评分相关p<0.031。

临床怎么用

  • 临床决策中不应仅凭生活质量评分推断患者对VAD治疗的偏好。
  • 需结合患者对疾病的感知和预期生存理解,个体化讨论晚期心衰治疗方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Registry Evaluation of Vital Information for Ventricular Assist Devices (VADs) in Ambulatory Life study is a prospective multicenter cohort of 400 ambulatory patients with advanced chronic systolic heart failure (HF). The aim of the study is to better understand disease trajectory and optimal timing of advanced HF therapies. We examined patient health-related quality of life (HRQOL) data collected at enrollment and their association with patient treatment preferences for VAD placement. METHODS: Baseline assessment of HRQOL included the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the EuroQol EQ-5D-3L Visual Analogue Scale (VAS), along with patient self-assessment of remaining life (PSARL). Descriptive statistics were used to present baseline HRQOL data and Spearman correlation tests to assess the association between KCCQ, VAS, and VAD treatment preference with patient clinical characteristics of interest. RESULTS: The median age was 60 years, 75% were male, and the median left ventricular ejection fraction was 20%. The median (25th percentile, 75th percentile), baseline KCCQ summary score was 64 (48, 78), VAS score 65 (50, 75), and PSARL 7 years (5, 10). There were statistically significant associations of baseline KCCQ and VAS with New York Heart Association class and Interagency Registry of Mechanically Assisted Circulatory Support profile (p < 0.005 for all comparisons). Baseline KCCQ and VAS revealed a modest association with PSARL (correlation = 0.45 and 0.35, respectively; p < 0.001), and many patients were overly optimistic about their expected survival. VAD treatment preference was associated with KCCQ scores (p < 0.031), but the absolute differences were small. VAD treatment preference was independent of other key clinical characteristics such as subject age, VAS, and PSARL. CONCLUSIONS: We found a lack of strong association between HRQOL and patient preference for VAD therapy. Better understanding of patients' perceptions of their illness and how this relates to HRQOL outcomes, clinician risk assessment, and patient decision-making is needed. This may in turn allow better guidance toward available HF therapies in this vulnerable population.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Stehlik J, Mountis M, Haas D, et al. Quality of life and treatment preference for ventricular assist device therapy in ambulatory advanced heart failure: A report from the REVIVAL study. J Heart Lung Transplant. 2019. PMID: 31822442. doi:10.1016/j.healun.2019.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。